Wockhardt is currently trading at Rs. 406.80, up by 18.75 points or 4.83% from its previous closing of Rs. 388.05 on the BSE.
The scrip opened at Rs. 402.25 and has touched a high and low of Rs. 408.10 and Rs. 398.90 respectively. So far 8202 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 804.50 on 26-May-2021 and a 52 week low of Rs. 379.80 on 27-Jan-2022.
Last one week high and low of the scrip stood at Rs. 408.10 and Rs. 386.50 respectively. The current market cap of the company is Rs. 4300.20 crore.
The promoters holding in the company stood at 67.13%, while Institutions and Non-Institutions held 3.04% and 29.83% respectively.
Wockhardt has received permission from the Central Drugs Standard Control Organization (CDSCO) to export up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I vaccine.
The company's Bulk vaccine and Fill-Finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively were jointly inspected and approved by Drug inspectors from CDSCO (West zone) & Aurangabad State FDA and Expert from CDL Kasauli to receive export NOC.
Wockhardt’s state-of-the-art automated manufacturing facilities in Aurangabad are dedicated to produce world class high quality injectable products. Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against COVID-19 based on the technology transfer from Gamaleya National Research Institute of Epidemiology and Microbiology.
Wockhardt is a research based global pharmaceutical and Biotech Company headquartered in Mumbai, India.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: